Skip to main content

Table 3 Changes of prothrombotic markers in patients with prostate cancer who underwent surgery with total intravenous anesthesia with target-controlled infusion (TIVA-TCI) before the induction of anaesthesia (T0), 1 hr post-surgery (T1) and 24 hrs post-surgery (T2)

From: Perioperative changes in pro and anticoagulant factors in prostate cancer patients undergoing laparoscopic and robotic radical prostatectomy with different anaesthetic techniques

  T0 T1 T2 P
     T0 vs T1 T1 vs T2 T0 vs T2
Screen clotting time       
- PT (%) 93.1 (1.3) 85.6 (1.2) 82.5 (1.2) 0.001 0.21 0.001
- PTT (sec) 29.6 (0.6) 26.8 (0.7) 27.6 (0.8) 0.003 0.07 0.18
Procoagulant markers       
- Fibrinogen (mg/dL) 285.5 (7.1) 262.3 (6.6) 353.3 (8.8) 0.004 0.001 0.001
- TAT (ng/L) 9.1 (1.9) 22.8 (3.2) 9.7 (2.4) 0.002 0.004 0.79
- F1 + 2 (pmol/L) 210.8 (27.3) 622.1 (64.2) 364.4 (45.6) 0.001 0.001 0.007
- FVIII (%) 142.9 (8.1) 194.2 (9.3) 162.3 (5.6) 0.001 0.004 0.04
Fibrinolysis markers       
- PAI-1 (ng/ml) 15.2 (1.4) 21.9 (5.8) 36.1 (9.8) 0.41 0.20 0.04
- D-dimer (μg/L) 127.1 (12.8) 721.4 (170.4) 364.2 (28.3) 0.001 0.02 0.001
Haemostatic system inhibitors       
- AT (%) 102.1 (1.8) 90.6 (1.9) 87.4 (2.4) 0.001 0.38 0.001
- protein C (%) 109.6 (2.8) 95.4 (2.8) 87.8 (2.8) 0.004 0.03 0.001
- protein S (%) 93.8 (3.1) 84.2 (2.8) 82.4 (2.4) 0.01 0.56 0.001
Platelet-aggregating properties       
- p-selectin (ng/ml) 37.9 (2.0) 36.8 (2.4) 33.5 (2.6) 0.78 0.37 0.28
  1. Values are mean (SD).